Khiron Life Sciences Corp. (TSXV:KHRN), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has launched its Latin America medical education program with a schedule of doctor training and learning events in Bogota, Colombia on January 21-23, and in Mexico City, Mexico on February 28. These events, with more than 300 health care professionals in attendance, reflect a growing relationship between Khiron, medical associations and health care professionals across the region to inform, educate and discuss medical cannabis knowledge and developments.

The Khiron medical education program is launching in Colombia and Mexico as part of a stated strategy to build a robust doctor network across Latin America through Khiron hosted and sponsored events and conferences, and with the endorsement of leading regional medical associations. Events are education based, with global research and insight on medical cannabis and information platforms to support doctors and health care professionals in providing medical cannabis treatment options.


Alvaro Torres, Co-founder and Chief Executive Officer, Khiron Life Sciences, commented; “The launch of our medical education program is integral to the Khiron business model and to our strategy to build a network of doctors and health care professionals across Latin America. We welcome and appreciate the endorsement of the Mexican College of Internal Medicine for KhironMed in Mexico, and look forward to working with their members as we expand our education program throughout the region.”

Dr. Maria Fernanda Arboleda MD, Khiron Medical Director, added; “As clinical research continues to escalate and to support the use of medical cannabis as a complementary treatment for several medical conditions, such as chronic pain and palliative care, it is crucial that we actively involve health care providers to share and discuss updated, comprehensive and reliable knowledge and how this information should be well-applied to meet patient needs in Colombia, Mexico and across Latin America.”

First Khiron ILANS Medical Cannabis Course 2019 – Bogota, Colombia

The first Khiron ILANS Medical Cannabis Course is a three-day hosted in Bogota, Colombia from January 21-23, 2019, and will provide research-based, global knowledge on medical cannabis, with presentations led by Dr. Maria Fernanda Arboleda MD, Khiron Medical Director and insight from Jairo Espinoza, founder of ILANS medical clinics and Khiron VP of Medical Affairs. The course will also discuss current and future Colombian medical cannabis legislation with Juan Diego Alvarez, Khiron VP of Regulations

Course presentations will feature sessions with international medical leaders, including renown palliative care and medical cannabis specialist Dr. Michael Dworkind,who has trained multiple health care providers in Canada, as well as pharmaceutical clinical consultant and educator, Pharmacist Michael Bolvin, as the event brings together Presidents of Colombia´s leading Medical Associations , doctors and health care professionals in a learning environment with modules designed to detail and review medical cannabis considerations and treatment for certain patient conditions.

KhironMed 2019 – Mexico City, Mexico

KhironMed 2019 will be hosted by Khiron in Mexico City, Mexico on February 28, 2019 with an opening presentation by Mr. Vicente Fox former President of Mexico and Khiron board member. The one-day symposium which is endorsed by Centro Fox, will welcome prominent doctors and health care professionals and feature keynote presentations by Dr. Maria Fernanda Arboleda MD, Khiron Medical Director, Dr. Ethan Russo, currently Director of Research and Development at the International Cannabis and Cannabinoids Institute and Dr. Edwin Bendek, dermatologist, specialist in anti-aging and regenerative medicine and CBD based cosmeceuticals, among other speakers. For more information about this event visit https://khironmed.com/

Khiron has received the endorsement of the Mexican College of Internal Medicine for the KhironMed as well as for a schedule of medical education symposium and activities taking place across Mexico in 2019.

Dr. Roberto Lopez Espinoza, president of the Mexican College of Internal Medicine, A.C stated, “Through this event, we will train health leaders in the areas of safe use and prescription of medicinal cannabis, seeking to ensure that the learning objectives are achieved throughout the day.”

About the Mexican College of Internal Medicine

The Mexican College of Internal Medicine is a medical institution that seeks to consolidate and guide the presence of internal medicine in Mexico.  Among its main objectives are to promote, foster, advise and carry out academic research and continuing education activities that encourage the development and highest level of internal medicine, as well as to provide access to experts in financial and legislative issues. For further information visit https://www.cmim.org/

About Khiron Life Sciences

Khiron Life Sciences Corp.  is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis companies to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/

Cautionary Notes

Market and Industry Data

This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by  statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the final acceptance of the TSXV and the commencement of sales in Mexico. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: dcollins@khiron.ca; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation. 

Source: www.newswire.ca

CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).

The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.

Keep reading... Show less

Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands

In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.

Keep reading... Show less

Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.

Keep reading... Show less

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).

Keep reading... Show less

Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.

Keep reading... Show less